Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adapt Alec trial
2023-506886-76-00Phase 4Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised trial of alectinib in ALK-positive non-small cell lung cancer (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Progression-free survival in low-exposure subgroup. Planned start Jan 2024; status: authorised.
02
Drugs
alectinib
03
Conditions
ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on 2023-506886-76-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506886-76-00.